Details of the Drug

General Information of Drug (ID: DMH32LC)

Drug Name
ISIS-DMPK
Indication
Disease Entry ICD 11 Status REF
Myotonic dystrophy 8C71.0 Phase 1/2 [1]
Drug Type
Antisense drug
Cross-matching ID
TTD ID
D0X9WC

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DMPK messenger RNA (DMPK mRNA) TTZQTY2 DMPK_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02312011) A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
3 Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 2012 Jun 1;3(6):699-709.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1505).